Đang hiển thị 1 - 20 kết quả của 144 cho tìm kiếm '"Drug Resistance"', thời gian truy vấn: 0.02s Tinh chỉnh kết quả
  1. 1
    Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

    Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness Bằng Alex C.H. Liu (14961921)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

    Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness Bằng Alex C.H. Liu (14961921)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

    Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness Bằng Alex C.H. Liu (14961921)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

    Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness Bằng Alex C.H. Liu (14961921)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

    Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness Bằng Alex C.H. Liu (14961921)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness

    Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness Bằng Alex C.H. Liu (14961921)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant N... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant N... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

    Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant... Bằng Seung Yeon Oh (15051017)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

    Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer Bằng Nicole A. Traphagen (16677391)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

    Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer Bằng Nicole A. Traphagen (16677391)

    Được phát hành 2025
    Những chủ đề:
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: